Medpace Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 71 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 546.54.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Medpace Holdings Inc is 8.82, ranking 27 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 659.90M, representing a year-over-year increase of 23.74%, while its net profit experienced a year-over-year increase of 15.25%.
Key Metrics
The current valuation score of Medpace Holdings Inc is 5.84, ranking 362 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 36.96, which is 21.55% below the recent high of 44.93 and 44.47% above the recent low of 20.52.
The current earnings forecast score of Medpace Holdings Inc is 5.69, ranking 351 out of 392 in the Biotechnology & Medical Research industry. The average price target is 567.50, with a high of 655.00 and a low of 302.21.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Medpace Holdings Inc is 6.69, ranking 191 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 601.21 and the support level at 510.58, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Medpace Holdings Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 87.06%, representing a quarter-over-quarter decrease of 8.33%. The largest institutional shareholder is The Vanguard, holding a total of 2.26M shares, representing 8.01% of shares outstanding, with 8.93% decrease in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Medpace Holdings Inc is 7.52, ranking 11 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.41. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
